ReviewWorld journal of diabetes2017
Statins redux: A re-assessment of how statins lower plasma cholesterol.
Review in World journal of diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Tissue-Specific Chemerin in Atherosclerosis.Biomolecules · 2026Review
- Treatment of Ezetimibe lowers total and low-density lipoprotein cholesterol in hypercholesterolemic dogs with hyperadorenocorticism.The Journal of veterinary medical science · 2024Article
- Two Triterpenoids, ARM-2 and RA-5, FromJournal of lipids · 2024Article
- Triterpenoids fromACS omega · 2023Article
- Development and validation of an eco-friendly HPLC-UV method for determination of atorvastatin and vitamin DBMC chemistry · 2023Article
- Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis.European journal of hospital pharmacy : science and practice · 2023Article
- Egyptian practical guidance in lipid management 2020.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021Review
- Rosuvastatin protects against endothelial cell apoptosisExperimental and therapeutic medicine · 2020Article
- Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.Endocrinology and metabolism (Seoul, Korea) · 2020Observational
- Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review.Current cardiology reviews · 2020Review
- Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs.Pharmacy (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity associated dyslipidemia and its negative effects on the heart and blood vessels have emerged as a major healthcare challenge around the globe. The use of statins, potent inhibitors of hydroxyl-methyl glutaryl (HMG) Co-A reductase, a rate-limiting enzyme in cholesterol biosynthesis, has significantly reduced the rates of cardiovascular and general mortality in patients with coronary artery disease. How statins lower plasma cholesterol levels presents a mechanistic conundrum since persistent exposure to these drugs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.